前沿生物-U
(688221)
| 流通市值：57.39亿 | | | 总市值：57.39亿 |
| 流通股本：3.75亿 | | | 总股本：3.75亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 97,399,221.59 | 167,678,148.86 | 221,972,966.63 | 248,982,710.82 |
| 交易性金融资产 | 594,745,179.92 | 559,583,896.87 | 524,124,461.9 | 600,530,908.31 |
| 应收票据及应收账款 | 62,906,181.25 | 46,132,395.99 | 38,143,925.97 | 34,750,381.75 |
| 其中：应收票据 | 3,621,455 | 1,000,000 | - | - |
| 应收账款 | 59,284,726.25 | 45,132,395.99 | 38,143,925.97 | 34,750,381.75 |
| 预付款项 | 10,726,540.36 | 16,998,886.48 | 13,631,456.2 | 11,371,343.74 |
| 其他应收款合计 | 219,289,873.77 | 215,792,137.23 | 230,454,139.14 | 227,698,043.26 |
| 其中:应收利息 | 8,539,744.86 | 6,283,593.48 | 4,008,483.42 | 1,580,575.37 |
| 存货 | 48,509,627.4 | 62,057,129.47 | 45,395,961.38 | 41,060,199.74 |
| 其他流动资产 | 22,324,401.94 | 8,477,294.13 | 56,345,260.47 | 58,224,224.75 |
| 流动资产合计 | 1,055,901,026.23 | 1,076,719,889.03 | 1,130,068,171.69 | 1,222,617,812.37 |
| 非流动资产: | | | | |
| 长期股权投资 | 17,602,634.93 | 24,431,577.87 | 27,698,202.88 | 29,956,793.75 |
| 固定资产 | 426,669,436.06 | 236,845,758.29 | 240,692,776.45 | 245,000,007.14 |
| 在建工程 | 2,362,123.9 | 172,451,596.12 | 151,828,694.62 | 147,740,093.99 |
| 使用权资产 | 326,966.04 | 326,966.04 | 326,966.04 | 574,484.91 |
| 无形资产 | 132,938,433.63 | 138,323,359.1 | 143,731,427.14 | 149,322,190.61 |
| 长期待摊费用 | 1,589,768.73 | 1,735,137.31 | 1,883,902.08 | 2,034,364.98 |
| 其他非流动资产 | - | 12,393,614.64 | 27,512,658.44 | 14,892,431.98 |
| 非流动资产合计 | 581,489,363.29 | 586,508,009.37 | 593,674,627.65 | 589,520,367.36 |
| 资产总计 | 1,637,390,389.52 | 1,663,227,898.4 | 1,723,742,799.34 | 1,812,138,179.73 |
| 流动负债: | | | | |
| 短期借款 | 226,956,380.54 | 185,985,522.54 | 240,574,100.34 | 283,967,406.71 |
| 应付票据及应付账款 | 29,840,778.08 | 43,431,960.17 | 17,034,395.2 | 6,776,034.24 |
| 其中：应付票据 | - | 3,699,264.08 | 3,699,264.08 | - |
| 应付账款 | 29,840,778.08 | 39,732,696.09 | 13,335,131.12 | 6,776,034.24 |
| 预收款项 | 50,000 | - | - | - |
| 合同负债 | 1,820,247.11 | 1,852,230.77 | 1,841,351.53 | 2,676,810.67 |
| 应付职工薪酬 | 18,609,905.7 | 15,220,943.86 | 12,576,136.3 | 18,112,460.65 |
| 应交税费 | 870,059.75 | 821,774.11 | 801,351.95 | 808,358.56 |
| 其他应付款合计 | 18,352,384.63 | 15,732,932.73 | 19,889,636.1 | 23,156,351.64 |
| 一年内到期的非流动负债 | 93,896,507.62 | 110,481,155.44 | 122,543,301.52 | 59,585,223.25 |
| 其他流动负债 | 25,090.52 | 28,023.05 | 24,220.29 | 121,924.22 |
| 流动负债合计 | 390,421,353.95 | 373,554,542.67 | 415,284,493.23 | 395,204,569.94 |
| 非流动负债: | | | | |
| 长期借款 | 53,487,600 | 53,936,000 | 17,936,000 | 79,362,291.68 |
| 长期应付款 | 147,626,540.64 | 125,630,300 | 125,630,300 | 125,630,300 |
| 预计负债 | 2,352,034.28 | - | - | - |
| 递延收益 | 61,982,459.06 | 66,131,513.11 | 67,680,567.16 | 70,629,621.21 |
| 非流动负债合计 | 265,448,633.98 | 245,697,813.11 | 211,246,867.16 | 275,622,212.89 |
| 负债合计 | 655,869,987.93 | 619,252,355.78 | 626,531,360.39 | 670,826,782.83 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 374,578,653 | 374,578,653 | 374,578,653 | 374,578,653 |
| 资本公积 | 2,723,191,887.05 | 2,723,191,887.05 | 2,723,191,887.05 | 2,723,191,887.05 |
| 其他综合收益 | 40,289.69 | 39,515.33 | 44,318.39 | 22,758.93 |
| 未分配利润 | -2,116,290,428.15 | -2,053,834,512.76 | -2,000,603,419.49 | -1,956,481,902.08 |
| 归属于母公司股东权益合计 | 981,520,401.59 | 1,043,975,542.62 | 1,097,211,438.95 | 1,141,311,396.9 |
| 股东权益合计 | 981,520,401.59 | 1,043,975,542.62 | 1,097,211,438.95 | 1,141,311,396.9 |
| 负债和股东权益合计 | 1,637,390,389.52 | 1,663,227,898.4 | 1,723,742,799.34 | 1,812,138,179.73 |
| 公告日期 | 2025-10-31 | 2025-08-30 | 2025-04-30 | 2025-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |